Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Wave Life Sciences Ltd.NASDAQ: WVE
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 124.0% from a year ago
Cash & equivalents stood at $544.59M at the end of Q1 FY2026, up 124.0% from a year earlier and down 9.5% from the prior quarter. Over 3 fiscal years it compounded at +89.5% a year.
Context
- Cash & equivalents amounted to 93.3% of total assets at the end of Q1 FY2026, up 9.0 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +124.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 602.07M USD
- Year-over-year change
- +99.3%
- 4-year CAGR
- +41.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 602.07M | +99.3% |
| FY2024 | 2024-12-31 | 302.08M | +50.8% |
| FY2023 | 2023-12-31 | 200.35M | +126.4% |
| FY2022 | 2022-12-31 | 88.5M | -41.2% |
| FY2021 | 2021-12-31 | 150.56M | — |
Cash & Equivalents vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +124.0% is the highest of 11, against a peer median of -7.5%.
- Cash & equivalents amounts to 93.3% of total assets for WVE, versus a peer median of 24.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.71B USD | +53.4% | +24.1% | 30.7% | |
| Mar 2026 | $544.59M USD | +124.0% | +89.5% | 93.3% | |
| Mar 2026 | $464.45M USD | +92.8% | -6.1% | 14.6% | |
| Sep 2026 | $296.3M USD | -12.4% | +10.4% | 10.2% | |
| Mar 2026 | $211.38M USD | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $184.76M USD | +78.4% | +188.7% | 98.8% | |
| Mar 2026 | $155.66M USD | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | $134.7M USD | +6.2% | -33.3% | 17.8% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Sep 2026 | $62.74M USD | -72.3% | -17.3% | 3.6% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding WVE) | — | -7.5% | -7.8% | 24.2% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 150.56M | 88.5M | 200.35M | 302.08M | 602.07M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 21.09M | 1.42M | 1.28M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.42M | 2.11M | 4.02M | 7.35M | 3.08M |
| Total Current Assets | 162.56M | 98.54M | 235.37M | 320.39M | 614.81M |
| Property, Plant & Equipment (Net) | 40.64M | 44.13M | 35.72M | 28M | 19.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 3.81M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.8M | 3.72M | 3.86M | 3.82M | 16K |
| Total Non-current Assets | 44.44M | 47.85M | 39.58M | 31.81M | 23.69M |
| Total Assets | 207.01M | 146.39M | 274.95M | 352.21M | 638.5M |
| Account Payables | 7.28M | 16.92M | 12.84M | 16.26M | 15.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 37.1M | 31.56M | 150.06M | 65.97M | 44.44M |
| Other Current Liabilities | 10.18M | 12.29M | 14.07M | 15.36M | 18.08M |
| Total Current Liabilities | 64.2M | 71.52M | 186.44M | 110.95M | 95.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 77.48M | 79.77M | 15.6M | 6.1M | 7.8M |
| Other Non-current Liabilities | 7.87M | 8.06M | 7.87M | 7.87M | 0 |
| Total Non-current Liabilities | 110.31M | 119.96M | 48.88M | 31.74M | 17.2M |
| Total Liabilities | 174.51M | 191.48M | 235.32M | 142.69M | 112.27M |
| Common Stock | 749.85M | 802.83M | 935.37M | 1.18B | 1.62B |
| Retained Earnings | (805.51M) | (967.34M) | (1.02B) | (1.12B) | (1.33B) |
| Accumulated OCI | 181K | (29K) | (124K) | (262K) | (250K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 32.5M | (45.09M) | 39.63M | 209.52M | 526.23M |
| Total Debt | 29.92M | 37.61M | 32.12M | 25.4M | 17.77M |
| Net Debt | (120.65M) | (50.88M) | (168.23M) | (276.67M) | (584.3M) |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.